The short answer
Adverse effects divide into two kinds: those arising from something other than the intended action, and those that are the intended action carried too far. The second cannot be engineered away without weakening the drug, which makes it a different problem entirely.
Key facts
- Type 1
- Off-target or unrelated toxicity
- Type 2
- The intended mechanism, exceeded
- Type 1 example
- Idiosyncratic liver injury
- Type 2 example
- Gastroparesis from delayed emptying
- Type 1 remedy
- Improve selectivity
- Type 2 remedy
- Dose, titration, patient selection
Why the distinction is not academic
It determines whether the problem is soluble by chemistry. An off-target effect can in principle be engineered out by making a compound more selective, leaving the wanted action intact. An on-target effect taken too far cannot. Reducing it means reducing what the drug does, because they are the same thing.
How to tell which you are looking at
Ask whether the adverse effect would disappear in a hypothetically perfect version of the drug. Drug-induced liver injury would; it is not part of how any GLP-1 agonist is supposed to work. Gastroparesis would not, because delayed gastric emptying is the mechanism. That thought experiment separates the two reliably.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Why on-target effects define a class
They appear across every compound sharing the mechanism, at every generation, regardless of design improvements. Gastrointestinal effects have persisted through liraglutide, semaglutide, tirzepatide and retatrutide and will persist in anything engaging the same receptor, because they follow from receptor pharmacology rather than from any particular molecule.
What can be done about them anyway
Dose, titration schedule and patient selection. If an effect scales with exposure, lower exposure reduces it. If it attenuates with time, gradual escalation limits the peak. If it affects some people much more, identifying them in advance helps. None of these removes the effect; they manage where on the curve someone sits.
The one route that could separate them
Finding that the wanted and unwanted effects run through different pathways after all. The 2024 Nature work on dissociable hindbrain circuits for satiety and aversion is exactly this. If appetite suppression and nausea are separable rather than one signal, then what looked like an inseparable on-target cost becomes a selectivity problem, which chemistry can address.
Why this framing helps in reading safety claims
A claim that a new compound has better tolerability means something different depending on the type. Improved selectivity against an off-target effect is a real advance. A lower rate of an on-target effect may simply reflect lower exposure or slower titration, which is a dosing statement rather than a molecular one.
Quick reference
| Off-target | On-target, exceeded | |
|---|---|---|
| Arises from | Something other than the mechanism | The mechanism itself |
| Example | Idiosyncratic liver injury | Gastroparesis |
| Engineered away? | In principle, by selectivity | Not without weakening the drug |
| Managed by | Better molecules | Dose, titration, selection |
Frequently asked questions
How do I tell the two apart?
Ask whether the effect would disappear in a hypothetically perfect version of the drug. If it is the mechanism, it would not.
Why do gastrointestinal effects persist across every generation?
They follow from receptor pharmacology rather than from any particular molecule, so improved design does not remove them.
Can an on-target effect ever be separated?
Only if the wanted and unwanted effects turn out to run through different pathways, which the 2024 work on dissociable hindbrain circuits suggests may be possible.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedHuang KP et al., Dissociable hindbrain GLP1R circuits for satiety and aversion. Nature 2024 (PMID 38987598)pubmed.ncbi.nlm.nih.gov
- PubMedOlubodun T et al., Gastroparesis induced by GLP-1 receptor agonists: a systematic review. PLoS One 2026 (PMID 42594084)pubmed.ncbi.nlm.nih.gov
- PubMedBuckeridge C et al., Efficacy and safety of danuglipron in adults with obesity. Diabetes Obes Metab 2025 (PMID 40539310)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- What the SUSTAIN Programme Data ShowedVilsbøll and colleagues evaluated retinopathy data across the SUSTAIN trials. The title places the HbA1c reduction between the drug and the risk.
- Why Fixing Glucose Quickly Can Make the Eye Worse FirstRapid improvement in glycaemic control is associated with transient worsening of retinopathy. It predates every modern diabetes drug.
- A Third Way an Adverse Effect Can AriseSome effects follow not from the drug but from what the drug achieves. Any intervention producing the same change as fast would produce them too.
- Comparing Things That Were Never ComparedWhen no head-to-head exists, a network meta-analysis links treatments through shared comparators. It rests on an assumption worth understanding.
- A Second Entrant to Tirzepatide's MechanismVK2735 is a GIP/GLP-1 dual agonist - the same receptor pair as tirzepatide. Its Phase 2 VENTURE study ran 13 weeks, too short to compare with 72-week data.